Novaccess Global Inc XSNX

Healthcare Biotechnology

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

OTCPK:XSNX - Post by User

Novaccess Global Inc

Bullboard Posts

Post by pro_traderon Sep 08, 2008 10:25am

443 Views

Post# 15437940

Adding to recent gains!!!!

Momentum is picking up for shares of XSNX as the stock is up nearly 2% at the open. We are also bumping-up against the 50 day moving average which looks poised to be penetrated. The MACD differential is expanding and the stochastics is now in a strong uptrend...yet far from overbought. I see at least 25% upside in the near-term. The time to buy is NOW.

Bullboard Posts

Barrick Gold employees detained in Mali amid ongoing dispute